Bifogade filer
See Redeye's interview with CEO Richard Paxman
Kurs
-4,68%
Likviditet
3,28 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-11-14 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-19 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-20 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2020-05-27 | - | Årsstämma |
| 2020-05-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning PAX 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Redeye interviewed Richard Paxman regarding the Q4 report: https://fast.wistia.net/embed/iframe/ftxjerhhjx
Contacts
Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se
About Us
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 5,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK), Houston, Texas (US) and Toronto, Ontario (CA).
The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company’s Certified Adviser.